Bloomberg on MSN6d
Novo’s New Obesity Drug Disappoints Again, This Time in DiabetesNovo is counting on the new shot to help it defend against a growing number of competitors, led by Eli Lilly & Co., which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback